时间:2021-02-03 14:07:50人气:4837来源: 欧中之声
A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
Guangdong-Hong Kong-Macao students immerse in Xinjiang's culture
(9096)人喜欢2025-08-18Int'l friends witness grand opening of Yangjiang Fishing Season
(9098)人喜欢2025-08-17Discover Vietnam & Southeast Asia at the 2025 Southern China Book Fair
(10009)人喜欢2025-08-17What is the Pearl River? How China's second largest river transformed Lingnan!
(15471)人喜欢2025-08-14Tennis test event for China’s 15th National Games opens in Hengqin
(13271)人喜欢2025-08-13Video|Xinhui's 'Birds' Paradise': where nature makes you stay
(9126)人喜欢2025-08-12Data Pulse丨ACTIF 2025 Kicks Off: Unlocking Secrets Behind Success of Guangdong Animation
(9923)人喜欢2025-08-10DG CityBeat | What exciting innovations await at 15th China Int'l Animation Copyright Fair?
(15492)人喜欢2025-08-10